Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

A deal for depression diagnostics
June 2016
SHARING OPTIONS:

DARMSTADT, Germany—A new collaboration agreement focused on complementary diagnostics was announced in the second half of April between R-Biopharm AG and HMNC Brain Health. Per the deal, R-Biopharm AG will develop an in-vitro PCR-based genetic test with the goal of identifying ABCB1 gene variants in patients being treated with antidepressants in order to optimize the efficacy of depression therapy. The agreement covers the development, regulatory approval, manufacturing and commercialization of the ABCB1 test. No financial terms were disclosed.
 
“A laboratory test that supports the physician in his treatment decision to choose the best drug and the appropriate dose for the individual patient represents a major improvement in antidepressant treatment. To develop the ABCB1 test together with R-Biopharm is encouraging and an important step to achieve our ambitious goal even faster,” Prof. Florian Holsboer, CEO of HMNC Brain Health, remarked in a statement.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.